Jared Whitlock


Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

Biotechs (And Other Small Companies) May Lose Association Insurance Option

In a July letter to insurers the California Department of Managed Care, or CDMC, fired a warning shot against association health plans, in what could have wide-reaching impacts for biotechs, life sciences trade groups and other industries.

Tease photo

Cell Therapy Company Changes Name and Relocates HQ to Carlsbad

Lineage Underwent Corporate Restructuring, Co. to Focus on 3 Programs

BioTime is getting a new name — and a new headquarters.

Lyford Named to California’s Aging Stakeholder Advisory Committee

Shelley Lyford, the CEO of the nonprofit West Health, has been appointed to California’s Master Plan for Aging Stakeholder Advisory Committee.

Telemedicine Blossoming at San Diego Hospitals Amid Payment Reforms

Virtual Care Opens Lines Of Communication, Healing

Telemedicine is by no means new. But lagging insurance coverage and infrastructure costs prevented wide adoption. That’s changing,

Ionis’ Spinraza Gets Some Competition From Novartis’ SMA Treatment

Ionis Having Good Discussions With FDA on Other Therapeutic

Ionis Pharmaceuticals’ drug for a muscle-wasting disease continues to be the company’s main driver of growth, with competition looming.

Tease photo

Ra Medical Terminates CEO, Delays Q2 Results

Amid legal, manufacturing and financial challenges Ra Medical Systems delayed the release of second quarter results and fired its CEO.

Scripps Health Breaks Ground on $59M Cancer Center

A $59 million cancer center on the campus of Scripps Mercy Hospital that’s geared toward the central and southern parts of San Diego recently broke ground.

Q2 Life Sciences Footprint Expands By 263,399 Square Feet

Expansions By Some Of the Bigger Players Are Expected in Q3

The leasing footprint of San Diego life sciences companies grew by 263,399 square feet in the second quarter, according to report from the brokerage firm JLL.

Tease photo

Halozyme Reports Q2 Results

San Diego-based Halozyme reported $39.1 million in second quarter revenue, an 11% year-over-year increase.

Organovo Suspends Lead Program, to Explore ‘Strategic Alternatives’

Known for 3-D printed tissues that emulate human organs, Organovo plans to explore a merger, acquisition and other strategic alternatives.

More stories >>